Brief: Acelrx Pharmaceuticals Announces Publication Of Clinical Data Finding Potential Benefits Of Nafamostat Compared To Regional Citrate For Anticoagulation Of The Dialysis Circuit
29/03/2022 18:47
March 29 (Reuters) - AcelRx Pharmaceuticals Inc ACRX.O :
* ACELRX PHARMACEUTICALS ANNOUNCES PUBLICATION OF CLINICAL
DATA
FINDING POTENTIAL BENEFITS OF NAFAMOSTAT COMPARED TO REGIONAL
CITRATE FOR ANTICOAGULATION OF THE DIALYSIS CIRCUIT
Source text for Eikon: urn:newsml:reuters.com:*:nPn8PsBWDa
Further company coverage: ACRX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Talphera
See all newsTalphera Inc reports results for the quarter ended June 30 - Earnings Summary
Talphera Inc expected to post a loss of 7 cents a share - Earnings Preview
Talphera Q1 net loss narrows as costs rise on higher development spending
Talphera Q4 net loss widens as operating expenses rise
Brief: Talphera Announces 50% Enrollment Milestone In Ongoing Nephro-Crrt Registrational Trial